Organon & Co. (NYSE:OGN) Trading Down 4.4% – Time to Sell?

Shares of Organon & Co. (NYSE:OGN) fell 4.4% on Monday . The stock traded as low as $17.21 and last traded at $17.28. 354,409 shares traded hands during trading, a decline of 84% from the average session volume of 2,173,754 shares. The stock had previously closed at $18.07.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on OGN shares. JPMorgan Chase & Co. lowered shares of Organon & Co. from a “neutral” rating to an “underweight” rating and increased their price objective for the stock from $18.00 to $20.00 in a research note on Friday, September 6th. Evercore ISI upgraded Organon & Co. to a “strong-buy” rating in a research report on Wednesday, September 18th.

Organon & Co. Trading Down 6.5 %

The firm has a market capitalization of $4.35 billion, a P/E ratio of 3.35, a PEG ratio of 0.85 and a beta of 0.84. The business’s 50 day moving average is $19.38 and its two-hundred day moving average is $20.13. The company has a quick ratio of 1.17, a current ratio of 1.64 and a debt-to-equity ratio of 60.05.

Organon & Co. (NYSE:OGN) last released its quarterly earnings results on Thursday, October 31st. The company reported $0.87 EPS for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.03). The company had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.56 billion. Organon & Co. had a return on equity of 2,437.43% and a net margin of 20.30%. The firm’s quarterly revenue was up 4.1% compared to the same quarter last year. During the same quarter last year, the firm posted $0.78 earnings per share. Analysts expect that Organon & Co. will post 4.04 EPS for the current year.

Organon & Co. Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 12th. Stockholders of record on Tuesday, November 12th will be given a dividend of $0.28 per share. This represents a $1.12 annualized dividend and a dividend yield of 6.63%. The ex-dividend date is Tuesday, November 12th. Organon & Co.’s dividend payout ratio (DPR) is presently 22.22%.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of OGN. Versant Capital Management Inc raised its holdings in shares of Organon & Co. by 200.2% in the 2nd quarter. Versant Capital Management Inc now owns 1,207 shares of the company’s stock worth $25,000 after purchasing an additional 805 shares in the last quarter. William B. Walkup & Associates Inc. acquired a new position in shares of Organon & Co. in the second quarter worth $31,000. Fidelis Capital Partners LLC bought a new stake in shares of Organon & Co. during the 1st quarter worth about $43,000. Abich Financial Wealth Management LLC boosted its position in shares of Organon & Co. by 5,646.3% in the third quarter. Abich Financial Wealth Management LLC now owns 2,356 shares of the company’s stock valued at $45,000 after acquiring an additional 2,315 shares during the period. Finally, Atlas Capital Advisors LLC raised its holdings in Organon & Co. by 2,236.5% in the 2nd quarter. Atlas Capital Advisors LLC now owns 2,243 shares of the company’s stock valued at $46,000 after acquiring an additional 2,147 shares in the last quarter. Institutional investors own 77.43% of the company’s stock.

About Organon & Co.

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.